Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide Maintenance for Primary Multiple Myeloma
NCT05378971Unknown
- Sponsor
- Lanzhou University
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Lanzhou University. Primary endpoint: 2-year Progression-Free Survival. Status: unknown.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05378971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378971.